Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag for chemotherapy-induced thrombocytopenia
CTR20190879Phase 3Suspended
- Sponsor
- Hengrui Therapeutics
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hetrombopag in chemotherapy-induced thrombocytopenia (CIT), sponsored by Hengrui Therapeutics. Started May 2019; status: suspended.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on CTR20190879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190879.